A phase 3, open‐label, single‐arm study of vadadustat for anemia in chronic kidney disease for Japanese patients on hemodialysis not receiving erythropoiesis‐stimulating agents

Vadadustat is an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor approved in Japan for the treatment of anemia in patients with chronic kidney disease (CKD). This phase 3, open‐label, single‐arm study evaluated the efficacy and safety of vadadustat in 24 Japanese patients with CKD‐associa...

Descripción completa

Detalles Bibliográficos
Autores principales: Nangaku, Masaomi, Kondo, Kazuoki, Takabe, Souichirou, Ueta, Kiichiro, Tandai, Tsubasa, Kawaguchi, Yutaka, Komatsu, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292398/
https://www.ncbi.nlm.nih.gov/pubmed/34115437
http://dx.doi.org/10.1111/1744-9987.13699

Ejemplares similares

Ejemplares similares